About Tezcat Biosciences:
Tezcat Biosciences is developing a portfolio of protein-drug conjugates to provide therapeutic options for patients harboring mutant RAS cancers. Our current portfolio consists of conjugates combining our proprietary protein carrier with established drug payloads. To-date, Tezcat's drug development has been supported by academic collaborations and government awards.
Born out of NYU Langone Health, our team is committed to refining and delivering the leading-edge technology from bench to bedside. Tezcat Biosciences has participated in the following programs:
Financial Conflict of Interest (FCOI) Policy for National Institutes of Health (NIH) grants. Read the policy here.
Tezcat Biosciences is developing a portfolio of protein-drug conjugates to provide therapeutic options for patients harboring mutant RAS cancers. Our current portfolio consists of conjugates combining our proprietary protein carrier with established drug payloads. To-date, Tezcat's drug development has been supported by academic collaborations and government awards.
Born out of NYU Langone Health, our team is committed to refining and delivering the leading-edge technology from bench to bedside. Tezcat Biosciences has participated in the following programs:
- 2023 NCI Investor Initiative Award, part of National Cancer Institute SBIR program
- 2023 START-UP NY Program, part of Empire State Development
- 2022 BMS Golden Ticket Award, for lab space at BioLabs @NYULangone
- 2021 TMC Accelerator for Cancer Therapeutics, part of TMC Innovation and funded by Cancer Prevention and Research Institute of Texas (CPRIT)
- 2020 JLABs Virtual Program, part of Johnson & Johnson Innovation
- 2018 Entrepreneurship Lab (ELab) Program, an initiative of NYC's Economic Development Corporation (NYCEDC).
Financial Conflict of Interest (FCOI) Policy for National Institutes of Health (NIH) grants. Read the policy here.